Dr. Robert Lasser (Rob), a board-certified psychiatrist with extensive experience in academic medicine, clinical practice, and pharmaceutical industry research, has published 80+ peer-reviewed articles across child, adult, and geriatric mental health topics. Current focus in mood, neurodegenerative disorders; zuranolone, brexanolone. After obtaining his BA and MD degrees, Dr. Lasser completed Adult and Geriatric Psychiatry training with research into late-life depression, dementia, and structural neuroimaging, publishing on mood disorders, geriatric psychopharmacology, and dementia biology. Following his transition to industry, Rob held roles of increasing responsibility in operational and medical leadership for neuroscience development and commercialization, having led multiple global programs and product launches at Top-10 pharmaceutical manufacturers as both medical leader and general manager. In parallel, Dr. Lasser has maintained clinical practice in geriatric psychotherapy and psychopharmacology, major mental illness, and substance dependence for nearly 20 years. Dr. Lasser added to his formal education by completing an MBA in 2006.Specialties: Adult Psychiatry, Geriatric Psychiatry (including neuodegeneration), Pharmaceutical Development (IND, FIH and concept proof trials, global Phase 3 development programs, NDA filing, and post-NDA and lifecycle), Pharmaceutical Marketing and Strategy, Formal Business Education with emphasis on Management and Marketing (MBA), Ongoing Clinical Practice(s)